Akebia Therapeutics Wins US Patent for Vafseo With Term Through 2043

By Public Technologies
  • Akebia Therapeutics received a U.S. patent for Vafseo (vadadustat), with a term through January 18, 2043.
  • The patent covers methods for managing drug-drug interactions during vadadustat treatment; it is eligible for Orange Book listing.
  • Fourteen other vadadustat patents are listed in the Orange Book, with expiration dates between 2027 and 2036.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611171605PRIMZONEFULLFEED9879828) on November 17, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk